What's in Kyowa Kirin, Inc.'s pipeline?

Kyowa Kirin, Inc. has 7 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Kyowa Kirin, Inc.'s portfolio?

Top competitors by shared drug class: American Regent, Inc., Apnimed, Department of Medical Services Ministry of Public Health of Thailand, Eli Lilly and Company, Genzyme, a Sanofi Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kyowa-kirin-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kyowa Kirin, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kyowa Kirin, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Oral Phosphate Supplement	Oral Phosphate Supplement	marketed
active vitamin D	active vitamin D	phase 3	Vitamin D analog	Vitamin D receptor	Endocrinology
Istradefylline (KW-6002)	Istradefylline (KW-6002)	phase 3	Adenosine A2A receptor antagonist	Adenosine A2A receptor	Neurology

Therapeutic area mix

Endocrinology · 1
Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

American Regent, Inc. · 1 shared drug class
Apnimed · 1 shared drug class
Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Genzyme, a Sanofi Company · 1 shared drug class
Hospital Universitario de Canarias · 1 shared drug class
Joslin Diabetes Center · 1 shared drug class
LEO Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kyowa Kirin, Inc.:

Cite this brief

Drug Landscape (2026). Kyowa Kirin, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kyowa-kirin-inc. Accessed 2026-05-16.